Status:
TERMINATED
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Adrenocortical Carcinoma
Adrenocortical Cancer
Eligibility:
All Genders
2+ years
Brief Summary
Background: Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with advanced stages of ACC. Some people may live with ACC for years; others live for just months. Treat...
Detailed Description
Background: * Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% an...
Eligibility Criteria
Inclusion
- INCLUSION CRITIERIA:
- Subjects enrolled into NCI protocol 19C0016 Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
- Subjects with histologically or cytologically documented ACC.
- Age greater than or equal to 2 years old
- Ability of subject or parent/guardian to understand and the willingness to sign a written consent document.
- EXCLUSION CRITIERIA:
- None
Exclusion
Key Trial Info
Start Date :
June 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 12 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04447014
Start Date
June 25 2020
End Date
January 12 2023
Last Update
January 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892